JP2008533079A - 抗炎症化合物 - Google Patents
抗炎症化合物 Download PDFInfo
- Publication number
- JP2008533079A JP2008533079A JP2008501223A JP2008501223A JP2008533079A JP 2008533079 A JP2008533079 A JP 2008533079A JP 2008501223 A JP2008501223 A JP 2008501223A JP 2008501223 A JP2008501223 A JP 2008501223A JP 2008533079 A JP2008533079 A JP 2008533079A
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- butyl ester
- carboxylic acid
- piperidine
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims description 113
- 230000003110 anti-inflammatory effect Effects 0.000 title description 5
- 229940123142 Steroid sulfatase inhibitor Drugs 0.000 claims abstract description 65
- 238000011282 treatment Methods 0.000 claims abstract description 21
- 238000004519 manufacturing process Methods 0.000 claims abstract description 9
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 description 104
- 239000002904 solvent Substances 0.000 description 67
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 66
- 125000000753 cycloalkyl group Chemical group 0.000 description 63
- 125000000217 alkyl group Chemical group 0.000 description 54
- 239000000243 solution Substances 0.000 description 54
- 125000001424 substituent group Chemical group 0.000 description 54
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 50
- 125000004432 carbon atom Chemical group C* 0.000 description 43
- 238000001704 evaporation Methods 0.000 description 43
- 230000008020 evaporation Effects 0.000 description 43
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 42
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 34
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 32
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 29
- 239000012044 organic layer Substances 0.000 description 29
- -1 1,2-dihydrobenzopyranyl Chemical group 0.000 description 26
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 26
- 229910052739 hydrogen Inorganic materials 0.000 description 25
- 239000001257 hydrogen Substances 0.000 description 25
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
- 238000012360 testing method Methods 0.000 description 23
- 239000003098 androgen Substances 0.000 description 22
- 229910052799 carbon Inorganic materials 0.000 description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 239000012267 brine Substances 0.000 description 21
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 21
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 20
- 150000003053 piperidines Chemical class 0.000 description 20
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 20
- 150000003839 salts Chemical group 0.000 description 19
- 229920006395 saturated elastomer Polymers 0.000 description 19
- 125000000623 heterocyclic group Chemical group 0.000 description 18
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 16
- 238000003556 assay Methods 0.000 description 16
- 239000000872 buffer Substances 0.000 description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 15
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 13
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 13
- 125000003118 aryl group Chemical group 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- 210000003491 skin Anatomy 0.000 description 13
- 239000007858 starting material Substances 0.000 description 13
- 208000002874 Acne Vulgaris Diseases 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- 206010000496 acne Diseases 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 229910052736 halogen Inorganic materials 0.000 description 12
- 239000000741 silica gel Substances 0.000 description 12
- 229910002027 silica gel Inorganic materials 0.000 description 12
- 201000004384 Alopecia Diseases 0.000 description 11
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 11
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 11
- 230000001419 dependent effect Effects 0.000 description 11
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 10
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 10
- 150000002431 hydrogen Chemical class 0.000 description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 10
- 206010068168 androgenetic alopecia Diseases 0.000 description 9
- 239000003054 catalyst Substances 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 150000002367 halogens Chemical class 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- UAMKYJOZSURAIR-UHFFFAOYSA-N 4-bromo-2,5-dichlorothiophene-3-sulfonamide Chemical compound NS(=O)(=O)C1=C(Cl)SC(Cl)=C1Br UAMKYJOZSURAIR-UHFFFAOYSA-N 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 108010087999 Steryl-Sulfatase Proteins 0.000 description 8
- 102100038021 Steryl-sulfatase Human genes 0.000 description 8
- 238000002523 gelfiltration Methods 0.000 description 8
- 239000012074 organic phase Substances 0.000 description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 8
- 238000010898 silica gel chromatography Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 101000661600 Homo sapiens Steryl-sulfatase Proteins 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 201000002996 androgenic alopecia Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 229910000104 sodium hydride Inorganic materials 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 125000001544 thienyl group Chemical group 0.000 description 7
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 6
- UQRLSJLFAHCJBF-UHFFFAOYSA-N 3,5-bis(trifluoromethyl)benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 UQRLSJLFAHCJBF-UHFFFAOYSA-N 0.000 description 6
- 206010020112 Hirsutism Diseases 0.000 description 6
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 229920004890 Triton X-100 Polymers 0.000 description 6
- 239000013504 Triton X-100 Substances 0.000 description 6
- RVKFQAJIXCZXQY-CBZIJGRNSA-N [(8r,9s,13s,14s)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-yl] sulfamate Chemical compound NS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 RVKFQAJIXCZXQY-CBZIJGRNSA-N 0.000 description 6
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 6
- 125000003277 amino group Chemical group 0.000 description 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 6
- 125000004093 cyano group Chemical group *C#N 0.000 description 6
- 229940011871 estrogen Drugs 0.000 description 6
- 239000000262 estrogen Substances 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 6
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 206010039792 Seborrhoea Diseases 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 5
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 5
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 5
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 5
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 description 5
- 150000004885 piperazines Chemical class 0.000 description 5
- 208000008742 seborrheic dermatitis Diseases 0.000 description 5
- 239000012453 solvate Chemical group 0.000 description 5
- 239000003270 steroid hormone Substances 0.000 description 5
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 4
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229940030486 androgens Drugs 0.000 description 4
- ZDQSOHOQTUFQEM-PKUCKEGBSA-N ascomycin Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C\C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](O)[C@H](OC)C1 ZDQSOHOQTUFQEM-PKUCKEGBSA-N 0.000 description 4
- ZDQSOHOQTUFQEM-XCXYXIJFSA-N ascomycin Natural products CC[C@H]1C=C(C)C[C@@H](C)C[C@@H](OC)[C@H]2O[C@@](O)([C@@H](C)C[C@H]2OC)C(=O)C(=O)N3CCCC[C@@H]3C(=O)O[C@H]([C@H](C)[C@@H](O)CC1=O)C(=C[C@@H]4CC[C@@H](O)[C@H](C4)OC)C ZDQSOHOQTUFQEM-XCXYXIJFSA-N 0.000 description 4
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 4
- NPHXBWOWMHQCHB-UHFFFAOYSA-N ethyl 1-piperidin-4-ylcyclopentane-1-carboxylate Chemical compound C1CNCCC1C1(C(=O)OCC)CCCC1 NPHXBWOWMHQCHB-UHFFFAOYSA-N 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 230000003325 follicular Effects 0.000 description 4
- 125000001624 naphthyl group Chemical group 0.000 description 4
- 125000003386 piperidinyl group Chemical group 0.000 description 4
- 210000002374 sebum Anatomy 0.000 description 4
- GQMVREZHNFYRLM-UHFFFAOYSA-N tert-butyl 10-[[3,5-bis(trifluoromethyl)phenyl]sulfonylcarbamoyl]-8-azabicyclo[4.3.1]decane-8-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC2CCCCC1C2C(=O)NS(=O)(=O)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 GQMVREZHNFYRLM-UHFFFAOYSA-N 0.000 description 4
- XHBZKKFNCZNQFW-UHFFFAOYSA-N tert-butyl 2-ethylnonanoate Chemical compound CCCCCCCC(CC)C(=O)OC(C)(C)C XHBZKKFNCZNQFW-UHFFFAOYSA-N 0.000 description 4
- FMTMLJJFVOURSJ-UHFFFAOYSA-N (4-oxo-1-adamantyl) 3,3-dimethylbutanoate Chemical compound C1C(C2)CC3CC1(OC(=O)CC(C)(C)C)CC2C3=O FMTMLJJFVOURSJ-UHFFFAOYSA-N 0.000 description 3
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 3
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- ZLJHELYOGYUKRO-UHFFFAOYSA-N 1-[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]cyclopentane-1-carboxylic acid Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C1(C(O)=O)CCCC1 ZLJHELYOGYUKRO-UHFFFAOYSA-N 0.000 description 3
- GNIPIXWUGNCVFE-UHFFFAOYSA-N 2-[4-[2-[[3,5-bis(trifluoromethyl)phenyl]sulfonylamino]-2-oxoethyl]piperidin-1-yl]-4-(trifluoromethyl)benzamide Chemical compound NC(=O)C1=CC=C(C(F)(F)F)C=C1N1CCC(CC(=O)NS(=O)(=O)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CC1 GNIPIXWUGNCVFE-UHFFFAOYSA-N 0.000 description 3
- HATVPRAJGBKJGI-UHFFFAOYSA-N 2-[9-[(2-methylpropan-2-yl)oxycarbonyl]-9-azabicyclo[3.3.1]nonan-3-yl]acetic acid Chemical compound C1CCC2CC(CC(O)=O)CC1N2C(=O)OC(C)(C)C HATVPRAJGBKJGI-UHFFFAOYSA-N 0.000 description 3
- DKTZVQBJKORDTC-UHFFFAOYSA-N 2-fluoro-2-[3-[(2-methylpropan-2-yl)oxycarbonyl]-3-azabicyclo[3.3.1]nonan-9-ylidene]acetic acid Chemical compound C1CCC2CN(C(=O)OC(C)(C)C)CC1C2=C(F)C(O)=O DKTZVQBJKORDTC-UHFFFAOYSA-N 0.000 description 3
- VNBIOZLYENDPSF-UHFFFAOYSA-N 4-[(4-bromo-2,5-dichlorothiophen-3-yl)sulfonylcarbamoyl]piperidine-1-carboxylic acid Chemical compound C1CN(C(=O)O)CCC1C(=O)NS(=O)(=O)C1=C(Cl)SC(Cl)=C1Br VNBIOZLYENDPSF-UHFFFAOYSA-N 0.000 description 3
- FUYLLJCBCKRIAL-UHFFFAOYSA-N 4-methylumbelliferone sulfate Chemical compound C1=C(OS(O)(=O)=O)C=CC2=C1OC(=O)C=C2C FUYLLJCBCKRIAL-UHFFFAOYSA-N 0.000 description 3
- SDQWZHZNXQHXRQ-UHFFFAOYSA-N 8-[(2-methylpropan-2-yl)oxycarbonyl]-8-azabicyclo[4.3.1]decane-10-carboxylic acid Chemical compound C1CCCC2CN(C(=O)OC(C)(C)C)CC1C2C(O)=O SDQWZHZNXQHXRQ-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WFUSTZQXWRKPLT-UHFFFAOYSA-N C1CN(C(=O)O)CCC1(O)CS(=O)(=O)NC(C=1C=CC=CC=1)C1=CC=CC=C1 Chemical compound C1CN(C(=O)O)CCC1(O)CS(=O)(=O)NC(C=1C=CC=CC=1)C1=CC=CC=C1 WFUSTZQXWRKPLT-UHFFFAOYSA-N 0.000 description 3
- 239000005973 Carvone Substances 0.000 description 3
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
- XECPMHKLQSJYQD-UHFFFAOYSA-N [4-[2-[(4-bromo-2,5-dichlorothiophen-3-yl)sulfonylamino]-1-fluoro-2-oxoethylidene]-1-adamantyl] 3,3-dimethylbutanoate Chemical compound C1C(OC(=O)CC(C)(C)C)(CC2C3)CC3CC1C2=C(F)C(=O)NS(=O)(=O)C1=C(Cl)SC(Cl)=C1Br XECPMHKLQSJYQD-UHFFFAOYSA-N 0.000 description 3
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 229960003473 androstanolone Drugs 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 3
- WOBLPDAWNVAVAS-UHFFFAOYSA-N butyl carboxy carbonate Chemical compound CCCCOC(=O)OC(O)=O WOBLPDAWNVAVAS-UHFFFAOYSA-N 0.000 description 3
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- QOPVNWQGBQYBBP-UHFFFAOYSA-N chloroethyl chloroformate Chemical compound CC(Cl)OC(Cl)=O QOPVNWQGBQYBBP-UHFFFAOYSA-N 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 description 3
- 125000005169 cycloalkylcarbonylamino group Chemical group 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- DAOJNMSUUNAOQK-UHFFFAOYSA-N ethyl 1-pyridin-4-ylcyclopentane-1-carboxylate Chemical compound C=1C=NC=CC=1C1(C(=O)OCC)CCCC1 DAOJNMSUUNAOQK-UHFFFAOYSA-N 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 210000004209 hair Anatomy 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- UVNMQWKKZWSGDU-UHFFFAOYSA-N n-[3,5-bis(trifluoromethyl)phenyl]sulfonyl-1-(2-nitrophenyl)piperidine-4-carboxamide Chemical compound [O-][N+](=O)C1=CC=CC=C1N1CCC(C(=O)NS(=O)(=O)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CC1 UVNMQWKKZWSGDU-UHFFFAOYSA-N 0.000 description 3
- OSEGXVJHUKECHO-UHFFFAOYSA-N n-[3,5-bis(trifluoromethyl)phenyl]sulfonylpiperidine-4-carboxamide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(S(=O)(=O)NC(=O)C2CCNCC2)=C1 OSEGXVJHUKECHO-UHFFFAOYSA-N 0.000 description 3
- 125000001715 oxadiazolyl group Chemical group 0.000 description 3
- 125000004043 oxo group Chemical group O=* 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 3
- 125000004193 piperazinyl group Chemical group 0.000 description 3
- 229960002847 prasterone Drugs 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- 210000001732 sebaceous gland Anatomy 0.000 description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- GYPNSDVBMLOLIL-UHFFFAOYSA-N tert-butyl 10-oxo-8-azabicyclo[4.3.1]decane-8-carboxylate Chemical compound C1CCCC2CN(C(=O)OC(C)(C)C)CC1C2=O GYPNSDVBMLOLIL-UHFFFAOYSA-N 0.000 description 3
- JKSNPUYWGWJSDR-UHFFFAOYSA-N tert-butyl 3-(2-ethoxy-2-oxoethylidene)-9-azabicyclo[3.3.1]nonane-9-carboxylate Chemical compound C1CCC2CC(=CC(=O)OCC)CC1N2C(=O)OC(C)(C)C JKSNPUYWGWJSDR-UHFFFAOYSA-N 0.000 description 3
- JXVIMQYOMRSDKU-UHFFFAOYSA-N tert-butyl 3-[2-[(4-bromo-2,5-dichlorothiophen-3-yl)sulfonylamino]-1-cyano-2-oxoethylidene]-8-azabicyclo[3.2.1]octane-8-carboxylate Chemical compound CC(C)(C)OC(=O)N1C(C2)CCC1CC2=C(C#N)C(=O)NS(=O)(=O)C1=C(Cl)SC(Cl)=C1Br JXVIMQYOMRSDKU-UHFFFAOYSA-N 0.000 description 3
- YEKYAQUJESJBFI-UHFFFAOYSA-N tert-butyl 3-oxo-9-azabicyclo[3.3.1]nonane-9-carboxylate Chemical compound C1CCC2CC(=O)CC1N2C(=O)OC(C)(C)C YEKYAQUJESJBFI-UHFFFAOYSA-N 0.000 description 3
- OQFQSVLNHCIOTA-UHFFFAOYSA-N tert-butyl 4-(1-ethoxycarbonylcyclopentyl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C1(C(=O)OCC)CCCC1 OQFQSVLNHCIOTA-UHFFFAOYSA-N 0.000 description 3
- WKIRKOXUKDAGBJ-UHFFFAOYSA-N tert-butyl 4-[[3,5-bis(trifluoromethyl)benzoyl]sulfamoylmethyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1CS(=O)(=O)NC(=O)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 WKIRKOXUKDAGBJ-UHFFFAOYSA-N 0.000 description 3
- 229960003604 testosterone Drugs 0.000 description 3
- TZNOIZAKGIVWLK-PRHODGIISA-N (3S,4R)-4-[[3,5-bis(trifluoromethyl)phenyl]sulfonylcarbamoyl]-3-methylpiperidine-1-carboxylic acid Chemical compound C[C@@H]1CN(C(O)=O)CC[C@H]1C(=O)NS(=O)(=O)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 TZNOIZAKGIVWLK-PRHODGIISA-N 0.000 description 2
- TZNOIZAKGIVWLK-PELKAZGASA-N (3S,4S)-4-[[3,5-bis(trifluoromethyl)phenyl]sulfonylcarbamoyl]-3-methylpiperidine-1-carboxylic acid Chemical compound C[C@@H]1CN(C(O)=O)CC[C@@H]1C(=O)NS(=O)(=O)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 TZNOIZAKGIVWLK-PELKAZGASA-N 0.000 description 2
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 description 2
- WJIRTAAFTJFXIN-UHFFFAOYSA-N 1-[2-[[3,5-bis(trifluoromethyl)phenyl]sulfonylamino]-1-(4-chlorophenyl)-2-oxoethyl]-n-cyclohexylpiperidine-4-carboxamide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(S(=O)(=O)NC(=O)C(N2CCC(CC2)C(=O)NC2CCCCC2)C=2C=CC(Cl)=CC=2)=C1 WJIRTAAFTJFXIN-UHFFFAOYSA-N 0.000 description 2
- UPMLWWDXQWUWSX-UHFFFAOYSA-N 2,4,5-trichlorothiophene-3-sulfonamide Chemical compound NS(=O)(=O)C1=C(Cl)SC(Cl)=C1Cl UPMLWWDXQWUWSX-UHFFFAOYSA-N 0.000 description 2
- PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 2
- UYXWANJGLAAYMY-UHFFFAOYSA-N 2-[1-[2-carbamoyl-5-(trifluoromethyl)phenyl]piperidin-4-yl]acetic acid Chemical compound NC(=O)C1=CC=C(C(F)(F)F)C=C1N1CCC(CC(O)=O)CC1 UYXWANJGLAAYMY-UHFFFAOYSA-N 0.000 description 2
- SLXQRAMAAPBUQJ-UHFFFAOYSA-N 2-carbonoperoxoylbenzoic acid;magnesium;hexahydrate Chemical compound O.O.O.O.O.O.[Mg].OOC(=O)C1=CC=CC=C1C(O)=O SLXQRAMAAPBUQJ-UHFFFAOYSA-N 0.000 description 2
- DBTIPLXPONYLSL-UHFFFAOYSA-N 2-cyano-2-[8-[(2-methylpropan-2-yl)oxycarbonyl]-8-azabicyclo[3.2.1]octan-3-ylidene]acetic acid Chemical compound C1C(=C(C#N)C(O)=O)CC2CCC1N2C(=O)OC(C)(C)C DBTIPLXPONYLSL-UHFFFAOYSA-N 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- BTRCVKADYDVSLI-UHFFFAOYSA-N 3,5-bis(trifluoromethyl)benzenesulfonyl chloride Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(S(Cl)(=O)=O)=C1 BTRCVKADYDVSLI-UHFFFAOYSA-N 0.000 description 2
- YTPFTKZWNFGVNI-UHFFFAOYSA-N 4-[[3,5-bis(trifluoromethyl)benzoyl]sulfamoylmethylidene]piperidine-1-carboxylic acid Chemical compound C1CN(C(=O)O)CCC1=CS(=O)(=O)NC(=O)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 YTPFTKZWNFGVNI-UHFFFAOYSA-N 0.000 description 2
- PNGKOGPTCHCLPB-UHFFFAOYSA-N 4-hydroxy-4-(sulfamoylmethyl)piperidine-1-carboxylic acid Chemical compound NS(=O)(=O)CC1(O)CCN(C(O)=O)CC1 PNGKOGPTCHCLPB-UHFFFAOYSA-N 0.000 description 2
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010020864 Hypertrichosis Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- IYTXKIXETAELAV-UHFFFAOYSA-N Nonan-3-one Chemical compound CCCCCCC(=O)CC IYTXKIXETAELAV-UHFFFAOYSA-N 0.000 description 2
- KECYLNXRWDTNQX-LJGSYFOKSA-N OC(=O)NC[C@H]1CC[C@@H](CC1)C(=O)NS(=O)(=O)c1c(Cl)sc(Cl)c1Br Chemical compound OC(=O)NC[C@H]1CC[C@@H](CC1)C(=O)NS(=O)(=O)c1c(Cl)sc(Cl)c1Br KECYLNXRWDTNQX-LJGSYFOKSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- VCFVGOYKSFLJEV-UHFFFAOYSA-N [4-(2-ethoxy-1-fluoro-2-oxoethylidene)-1-adamantyl] 3,3-dimethylbutanoate Chemical compound C1C(C2)CC3C(=C(F)C(=O)OCC)C1CC2(OC(=O)CC(C)(C)C)C3 VCFVGOYKSFLJEV-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 description 2
- 125000005362 aryl sulfone group Chemical group 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229940000635 beta-alanine Drugs 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 125000006630 butoxycarbonylamino group Chemical group 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- FVPISMANESAJQZ-UHFFFAOYSA-N ethyl 2-diethoxyphosphoryl-2-fluoroacetate Chemical compound CCOC(=O)C(F)P(=O)(OCC)OCC FVPISMANESAJQZ-UHFFFAOYSA-N 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000016507 interphase Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 208000001875 irritant dermatitis Diseases 0.000 description 2
- SJFNDMHZXCUXSA-UHFFFAOYSA-M methoxymethyl(triphenyl)phosphanium;chloride Chemical compound [Cl-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(COC)C1=CC=CC=C1 SJFNDMHZXCUXSA-UHFFFAOYSA-M 0.000 description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N methyl acetate Chemical compound COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- KCQHPKSJDDMGGM-UHFFFAOYSA-N n-(4-chlorophenyl)sulfonyl-1-pentylbicyclo[2.2.2]octane-4-carboxamide Chemical compound C1CC(CCCCC)(CC2)CCC12C(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 KCQHPKSJDDMGGM-UHFFFAOYSA-N 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 125000000565 sulfonamide group Chemical group 0.000 description 2
- WZUZAFCRNMQFGC-UHFFFAOYSA-N tert-butyl 10-(methoxymethylidene)-8-azabicyclo[4.3.1]decane-8-carboxylate Chemical compound C1CCCC2CN(C(=O)OC(C)(C)C)CC1C2=COC WZUZAFCRNMQFGC-UHFFFAOYSA-N 0.000 description 2
- HTCVXQWTFREZQS-UHFFFAOYSA-N tert-butyl 10-formyl-8-azabicyclo[4.3.1]decane-8-carboxylate Chemical compound C1CCCC2CN(C(=O)OC(C)(C)C)CC1C2C=O HTCVXQWTFREZQS-UHFFFAOYSA-N 0.000 description 2
- JOJMXQFZIRHHIP-UHFFFAOYSA-N tert-butyl 3-(1-cyano-2-methoxy-2-oxoethylidene)-8-azabicyclo[3.2.1]octane-8-carboxylate Chemical compound C1C(=C(C#N)C(=O)OC)CC2CCC1N2C(=O)OC(C)(C)C JOJMXQFZIRHHIP-UHFFFAOYSA-N 0.000 description 2
- FIQGEHFGFKKYSU-UHFFFAOYSA-N tert-butyl 3-(2-ethoxy-2-oxoethyl)-9-azabicyclo[3.3.1]nonane-9-carboxylate Chemical compound C1CCC2CC(CC(=O)OCC)CC1N2C(=O)OC(C)(C)C FIQGEHFGFKKYSU-UHFFFAOYSA-N 0.000 description 2
- DATCBHNRXBEUIS-UHFFFAOYSA-N tert-butyl 3-[2-[(4-bromo-2,5-dichlorothiophen-3-yl)sulfonylamino]-2-oxoethyl]-9-azabicyclo[3.3.1]nonane-9-carboxylate Chemical compound CC(C)(C)OC(=O)N1C(C2)CCCC1CC2CC(=O)NS(=O)(=O)C1=C(Cl)SC(Cl)=C1Br DATCBHNRXBEUIS-UHFFFAOYSA-N 0.000 description 2
- QZGVSVXCVDPPCM-UHFFFAOYSA-N tert-butyl 4-[[3,5-bis(trifluoromethyl)benzoyl]sulfamoylmethyl]-4-hydroxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1(O)CS(=O)(=O)NC(=O)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 QZGVSVXCVDPPCM-UHFFFAOYSA-N 0.000 description 2
- FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 2
- OEQJOYQHIGIVTN-UHFFFAOYSA-N tert-butyl nonanoate Chemical compound CCCCCCCCC(=O)OC(C)(C)C OEQJOYQHIGIVTN-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- KPZSTOVTJYRDIO-UHFFFAOYSA-K trichlorocerium;heptahydrate Chemical compound O.O.O.O.O.O.O.Cl[Ce](Cl)Cl KPZSTOVTJYRDIO-UHFFFAOYSA-K 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 0 **S(NC(*(*)(*)N)=O)(=C)=O Chemical compound **S(NC(*(*)(*)N)=O)(=C)=O 0.000 description 1
- SJBBXFLOLUTGCW-UHFFFAOYSA-N 1,3-bis(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC(C(F)(F)F)=C1 SJBBXFLOLUTGCW-UHFFFAOYSA-N 0.000 description 1
- ULTHEAFYOOPTTB-UHFFFAOYSA-N 1,4-dibromobutane Chemical compound BrCCCCBr ULTHEAFYOOPTTB-UHFFFAOYSA-N 0.000 description 1
- AFNDANQXBDEYAI-UHFFFAOYSA-N 1-[2-(benzenesulfonamido)-1-[3,5-bis(trifluoromethyl)phenyl]-2-oxoethyl]-n-cyclohexylpiperidine-4-carboxamide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C(N2CCC(CC2)C(=O)NC2CCCCC2)C(=O)NS(=O)(=O)C=2C=CC=CC=2)=C1 AFNDANQXBDEYAI-UHFFFAOYSA-N 0.000 description 1
- PWKNBLFSJAVFAB-UHFFFAOYSA-N 1-fluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1F PWKNBLFSJAVFAB-UHFFFAOYSA-N 0.000 description 1
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- IAQHPZFALQQESM-UHFFFAOYSA-N 1-pentylbicyclo[2.2.2]octane-4-carboxylic acid Chemical compound C1CC2(C(O)=O)CCC1(CCCCC)CC2 IAQHPZFALQQESM-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- OKUSCHJUIFMPEC-UHFFFAOYSA-N 2-(4-chlorophenyl)-2-[4-(cyclohexylcarbamoyl)piperidin-1-yl]acetic acid Chemical compound C=1C=C(Cl)C=CC=1C(C(=O)O)N(CC1)CCC1C(=O)NC1CCCCC1 OKUSCHJUIFMPEC-UHFFFAOYSA-N 0.000 description 1
- MCTPIDIBCCWDQE-UHFFFAOYSA-N 2-[5-(3,3-dimethylbutanoyloxy)-2-adamantylidene]-2-fluoroacetic acid Chemical compound C1C(C2)CC3CC1(OC(=O)CC(C)(C)C)CC2C3=C(F)C(O)=O MCTPIDIBCCWDQE-UHFFFAOYSA-N 0.000 description 1
- PRCRODUOVHMKSH-UHFFFAOYSA-N 2-[5-(3,3-dimethylbutanoyloxy)-2-adamantylidene]-2-fluoroacetic acid [4-(2-ethoxy-1-fluoro-2-oxoethylidene)-1-adamantyl] 3,3-dimethylbutanoate Chemical compound C1C(C2)CC3CC1(OC(=O)CC(C)(C)C)CC2C3=C(F)C(O)=O.C1C(C2)CC3C(=C(F)C(=O)OCC)C1CC2(OC(=O)CC(C)(C)C)C3 PRCRODUOVHMKSH-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- XMTQQYYKAHVGBJ-UHFFFAOYSA-N 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA Chemical compound CN(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XMTQQYYKAHVGBJ-UHFFFAOYSA-N 0.000 description 1
- CEBLWTDFLDLHEH-UHFFFAOYSA-N 3-methyl-4-oxopiperidine-1-carboxylic acid Chemical compound CC1CN(C(O)=O)CCC1=O CEBLWTDFLDLHEH-UHFFFAOYSA-N 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KIDVSAGOGFQUTK-UHFFFAOYSA-N 4-[[3,5-bis(trifluoromethyl)benzoyl]sulfamoylmethyl]-4-hydroxypiperidine-1-carboxylic acid Chemical compound C1CN(C(=O)O)CCC1(O)CS(=O)(=O)NC(=O)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 KIDVSAGOGFQUTK-UHFFFAOYSA-N 0.000 description 1
- HHHDJHHNEURCNV-UHFFFAOYSA-N 4-chlorobenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=C(Cl)C=C1 HHHDJHHNEURCNV-UHFFFAOYSA-N 0.000 description 1
- HJGMRAKQWLKWMH-UHFFFAOYSA-N 8-methyl-8-azabicyclo[3.2.1]octan-3-amine Chemical compound C1C(N)CC2CCC1N2C HJGMRAKQWLKWMH-UHFFFAOYSA-N 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- GVPCAFVHVYHHGV-UHFFFAOYSA-N BrC=1C(=C(SC1Cl)Cl)S(=O)(=O)NC(CC1CC2CCCC(C1)N2C(=O)O)=O Chemical compound BrC=1C(=C(SC1Cl)Cl)S(=O)(=O)NC(CC1CC2CCCC(C1)N2C(=O)O)=O GVPCAFVHVYHHGV-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- ZBJYARLGYHDZQA-UHFFFAOYSA-N C(=O)(O)C(=C1CC2CCC(C1)N2C(=O)O)C#N Chemical compound C(=O)(O)C(=C1CC2CCC(C1)N2C(=O)O)C#N ZBJYARLGYHDZQA-UHFFFAOYSA-N 0.000 description 1
- DGDYJKSYFYRNMT-MGCOHNPYSA-N CC(C)(C)OC(=O)NC[C@H]1CC[C@@H](CC1)C(=O)NS(=O)(=O)c1c(Cl)sc(Cl)c1Br Chemical compound CC(C)(C)OC(=O)NC[C@H]1CC[C@@H](CC1)C(=O)NS(=O)(=O)c1c(Cl)sc(Cl)c1Br DGDYJKSYFYRNMT-MGCOHNPYSA-N 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical group Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000005262 Sulfatase Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000004190 benzothiazol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N=C(*)SC2=C1[H] 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- RMIBJVUYNZSLSD-UHFFFAOYSA-N bis[(1,1,1,3,3,3-hexafluoro-2-phenylpropan-2-yl)oxy]-diphenyl-$l^{4}-sulfane Chemical compound C=1C=CC=CC=1C(C(F)(F)F)(C(F)(F)F)OS(C=1C=CC=CC=1)(C=1C=CC=CC=1)OC(C(F)(F)F)(C(F)(F)F)C1=CC=CC=C1 RMIBJVUYNZSLSD-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 description 1
- 125000005167 cycloalkylaminocarbonyl group Chemical group 0.000 description 1
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
- LJOODBDWMQKMFB-UHFFFAOYSA-N cyclohexylacetic acid Chemical compound OC(=O)CC1CCCCC1 LJOODBDWMQKMFB-UHFFFAOYSA-N 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- KSMVZQYAVGTKIV-UHFFFAOYSA-N decanal Chemical compound CCCCCCCCCC=O KSMVZQYAVGTKIV-UHFFFAOYSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- KZTYYGOKRVBIMI-UHFFFAOYSA-N diphenyl sulfone Chemical compound C=1C=CC=CC=1S(=O)(=O)C1=CC=CC=C1 KZTYYGOKRVBIMI-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 210000000883 ear external Anatomy 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- QVLJLWHOILVHJJ-UHFFFAOYSA-N ethyl 2-pyridin-4-ylacetate Chemical compound CCOC(=O)CC1=CC=NC=C1 QVLJLWHOILVHJJ-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 125000006005 fluoroethoxy group Chemical group 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- TZBDEVBNMSLVKT-UHFFFAOYSA-N idramantone Chemical compound C1C(C2)CC3CC1(O)CC2C3=O TZBDEVBNMSLVKT-UHFFFAOYSA-N 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- SXQCTESRRZBPHJ-UHFFFAOYSA-M lissamine rhodamine Chemical compound [Na+].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S([O-])(=O)=O)C=C1S([O-])(=O)=O SXQCTESRRZBPHJ-UHFFFAOYSA-M 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- HOVAGTYPODGVJG-VEIUFWFVSA-N methyl alpha-D-mannoside Chemical compound CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O HOVAGTYPODGVJG-VEIUFWFVSA-N 0.000 description 1
- ANGDWNBGPBMQHW-UHFFFAOYSA-N methyl cyanoacetate Chemical compound COC(=O)CC#N ANGDWNBGPBMQHW-UHFFFAOYSA-N 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- PAMCRRDMORMCSM-UHFFFAOYSA-N n-(trifluoromethyl)benzamide Chemical compound FC(F)(F)NC(=O)C1=CC=CC=C1 PAMCRRDMORMCSM-UHFFFAOYSA-N 0.000 description 1
- NAYDFLVWRJIOAK-UHFFFAOYSA-N n-benzhydrylmethanesulfonamide Chemical compound C=1C=CC=CC=1C(NS(=O)(=O)C)C1=CC=CC=C1 NAYDFLVWRJIOAK-UHFFFAOYSA-N 0.000 description 1
- SUECUXVKMPTLRH-UHFFFAOYSA-N n-cyclohexylpiperidine-4-carboxamide Chemical compound C1CNCCC1C(=O)NC1CCCCC1 SUECUXVKMPTLRH-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- CTYRPMDGLDAWRQ-UHFFFAOYSA-N phenyl hydrogen sulfate Chemical compound OS(=O)(=O)OC1=CC=CC=C1 CTYRPMDGLDAWRQ-UHFFFAOYSA-N 0.000 description 1
- 238000005887 phenylation reaction Methods 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- UDSMCVVEFKCVIM-UHFFFAOYSA-N piperidin-4-yl acetate;hydrochloride Chemical compound Cl.CC(=O)OC1CCNCC1 UDSMCVVEFKCVIM-UHFFFAOYSA-N 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000033785 sebaceous gland development Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 150000005845 steroid sulfates Chemical class 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 108060007951 sulfatase Proteins 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- UOUFRTFWWBCVPV-UHFFFAOYSA-N tert-butyl 4-(2,4-dioxo-1H-thieno[3,2-d]pyrimidin-3-yl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CC1)n1c(=O)[nH]c2ccsc2c1=O UOUFRTFWWBCVPV-UHFFFAOYSA-N 0.000 description 1
- CAJUVPGXQHDOMM-UHFFFAOYSA-N tert-butyl 4-hydroxy-4-(sulfamoylmethyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(O)(CS(N)(=O)=O)CC1 CAJUVPGXQHDOMM-UHFFFAOYSA-N 0.000 description 1
- ROUYFJUVMYHXFJ-UHFFFAOYSA-N tert-butyl 4-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)CC1 ROUYFJUVMYHXFJ-UHFFFAOYSA-N 0.000 description 1
- IZUZIVIUDTZPFE-UHFFFAOYSA-N tert-butyl decanoate Chemical compound CCCCCCCCCC(=O)OC(C)(C)C IZUZIVIUDTZPFE-UHFFFAOYSA-N 0.000 description 1
- 125000004853 tetrahydropyridinyl group Chemical class N1(CCCC=C1)* 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- GGUBFICZYGKNTD-UHFFFAOYSA-N triethyl phosphonoacetate Chemical compound CCOC(=O)CP(=O)(OCC)OCC GGUBFICZYGKNTD-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- PXXNTAGJWPJAGM-UHFFFAOYSA-N vertaline Natural products C1C2C=3C=C(OC)C(OC)=CC=3OC(C=C3)=CC=C3CCC(=O)OC1CC1N2CCCC1 PXXNTAGJWPJAGM-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0505541.3A GB0505541D0 (en) | 2005-03-17 | 2005-03-17 | Organic compounds |
| PCT/EP2006/002382 WO2006097292A1 (en) | 2005-03-17 | 2006-03-15 | Anti-inflammatory compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008533079A true JP2008533079A (ja) | 2008-08-21 |
| JP2008533079A5 JP2008533079A5 (enExample) | 2009-04-16 |
Family
ID=34531452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008501223A Pending JP2008533079A (ja) | 2005-03-17 | 2006-03-15 | 抗炎症化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20090227620A1 (enExample) |
| EP (1) | EP1861098A1 (enExample) |
| JP (1) | JP2008533079A (enExample) |
| KR (1) | KR20070113226A (enExample) |
| CN (1) | CN101137375A (enExample) |
| AU (1) | AU2006224796A1 (enExample) |
| BR (1) | BRPI0607795A2 (enExample) |
| CA (1) | CA2599470A1 (enExample) |
| GB (1) | GB0505541D0 (enExample) |
| MX (1) | MX2007011320A (enExample) |
| RU (1) | RU2007138263A (enExample) |
| WO (1) | WO2006097292A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA200900960A1 (ru) * | 2007-01-31 | 2010-02-26 | Новартис Аг | Производные пиперидинацетамида для лечения воспалительных или аллергических заболеваний |
| CA2698814A1 (en) | 2007-09-17 | 2009-03-26 | Preglem S.A. | Treatment of oestrogen dependant conditions in pre-menopausal women |
| TW200936136A (en) * | 2008-01-28 | 2009-09-01 | Sanofi Aventis | Tetrahydroquinoxaline urea derivatives, their preparation and their therapeutic application |
| ES2555260T3 (es) | 2010-06-15 | 2015-12-30 | Bayer Intellectual Property Gmbh | Derivados de diamida de ácido antranílico |
| CN102657642B (zh) * | 2012-04-24 | 2014-01-15 | 广东省农业科学院兽医研究所 | Irosustat在制备抗柔嫩艾美耳球虫药物中的应用 |
| CA2874621A1 (en) | 2012-05-22 | 2013-11-28 | Genentech, Inc. | N-substituted benzamides and their use in the treatment of pain |
| CN107417601A (zh) * | 2017-04-06 | 2017-12-01 | 成都弥贝生物科技有限公司 | 具有抗菌活性的取代2‑酰胺磺酰基‑4,6‑芳基吡啶 |
| KR102458689B1 (ko) * | 2020-07-08 | 2022-10-25 | 원광대학교산학협력단 | 피페리딘 화합물 및 이의 제조 방법 |
| WO2025079965A1 (ko) * | 2023-10-10 | 2025-04-17 | 주식회사 넥시온바이오텍 | 치주 질환의 예방 또는 치료용 조성물 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002511459A (ja) * | 1998-04-09 | 2002-04-16 | ノバルティス アクチエンゲゼルシャフト | クロマノンおよびチオクロマノン誘導体 |
| WO2003082842A1 (en) * | 2002-03-28 | 2003-10-09 | Novartis Ag | Piperazinyl- or piperidinylamine-sulfamic acid amides as inhibitors of steroid sulfatase |
| JP2004506741A (ja) * | 2000-08-18 | 2004-03-04 | ステリックス リミテッド | ステロイドスルファターゼのインヒビターとしてのエストロゲン−１７−スルファメート |
| WO2004043968A1 (en) * | 2002-11-14 | 2004-05-27 | Novartis Ag | N-sulfonylaminothiazole |
| JP2005504643A (ja) * | 2001-10-03 | 2005-02-17 | エー アンド エー マニュファクチャリング カンパニー， インコーポレーテッド | 成形されたパネルを備えたベローズ |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR037097A1 (es) * | 2001-10-05 | 2004-10-20 | Novartis Ag | Compuestos acilsulfonamidas, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento |
-
2005
- 2005-03-17 GB GBGB0505541.3A patent/GB0505541D0/en not_active Ceased
-
2006
- 2006-03-15 JP JP2008501223A patent/JP2008533079A/ja active Pending
- 2006-03-15 EP EP06707567A patent/EP1861098A1/en not_active Withdrawn
- 2006-03-15 CA CA002599470A patent/CA2599470A1/en not_active Abandoned
- 2006-03-15 AU AU2006224796A patent/AU2006224796A1/en not_active Abandoned
- 2006-03-15 CN CNA2006800080245A patent/CN101137375A/zh active Pending
- 2006-03-15 US US11/908,895 patent/US20090227620A1/en not_active Abandoned
- 2006-03-15 RU RU2007138263/15A patent/RU2007138263A/ru not_active Application Discontinuation
- 2006-03-15 BR BRPI0607795-1A patent/BRPI0607795A2/pt not_active IP Right Cessation
- 2006-03-15 KR KR1020077021073A patent/KR20070113226A/ko not_active Withdrawn
- 2006-03-15 MX MX2007011320A patent/MX2007011320A/es not_active Application Discontinuation
- 2006-03-15 WO PCT/EP2006/002382 patent/WO2006097292A1/en not_active Ceased
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002511459A (ja) * | 1998-04-09 | 2002-04-16 | ノバルティス アクチエンゲゼルシャフト | クロマノンおよびチオクロマノン誘導体 |
| JP2004506741A (ja) * | 2000-08-18 | 2004-03-04 | ステリックス リミテッド | ステロイドスルファターゼのインヒビターとしてのエストロゲン−１７−スルファメート |
| JP2004506742A (ja) * | 2000-08-18 | 2004-03-04 | ステリックス リミテッド | ステロイドスルファターゼインヒビターおよび抗癌化合物としてのチオエーテル−スルファメートステロイド |
| JP2004511441A (ja) * | 2000-08-18 | 2004-04-15 | ステリックス リミテッド | ステロイドスルファターゼの阻害剤としての１７−アリール−リンカー誘導体化エストロゲン３−スルファメート |
| JP2005504643A (ja) * | 2001-10-03 | 2005-02-17 | エー アンド エー マニュファクチャリング カンパニー， インコーポレーテッド | 成形されたパネルを備えたベローズ |
| WO2003082842A1 (en) * | 2002-03-28 | 2003-10-09 | Novartis Ag | Piperazinyl- or piperidinylamine-sulfamic acid amides as inhibitors of steroid sulfatase |
| WO2004043968A1 (en) * | 2002-11-14 | 2004-05-27 | Novartis Ag | N-sulfonylaminothiazole |
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0607795A2 (pt) | 2009-06-13 |
| MX2007011320A (es) | 2007-11-08 |
| US20090227620A1 (en) | 2009-09-10 |
| AU2006224796A1 (en) | 2006-09-21 |
| CN101137375A (zh) | 2008-03-05 |
| KR20070113226A (ko) | 2007-11-28 |
| WO2006097292A1 (en) | 2006-09-21 |
| EP1861098A1 (en) | 2007-12-05 |
| GB0505541D0 (en) | 2005-04-27 |
| RU2007138263A (ru) | 2009-04-27 |
| CA2599470A1 (en) | 2006-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100952770B1 (ko) | 스테로이드 술파타제 억제제로서의 아실술폰아미드 | |
| AU2007210018A1 (en) | Amido compounds and their use as pharmaceuticals | |
| KR20090021193A (ko) | 트로판의 우레아 유도체, 그의 제법 및 그의 치료 용도 | |
| CA2419310A1 (en) | Substituted piperidines as melanocortin receptor agonists | |
| AU2005267289A1 (en) | N-substituted piperidines and their use as pharmaceuticals | |
| AU2005267331A1 (en) | Amido compounds and their use as pharmaceuticals | |
| BRPI0307267B1 (pt) | uso de compostos inibidores de beta-lactamases e composições farmacêuticas para terapia antibacteriana | |
| FR2873691A1 (fr) | Derives d'amino-piperidine, leur preparation et leur application en therapeutique | |
| AU2002350490A1 (en) | Acylsulfonamides as inhibitors of steroid sulfatase | |
| KR20070113226A (ko) | 소염 화합물 | |
| JP4580652B2 (ja) | ステロイドスルファターゼのインヒビターとしてのピペラジニル−またはピペリジニルアミンスルファミン酸アミド | |
| JP2008533080A (ja) | ステロイドスルファターゼ阻害剤とアスコマイシンの組合せ剤 | |
| JP2008508242A (ja) | アミノ−トロパン誘導体、その調製及び治療上のその使用 | |
| JP4551767B2 (ja) | Ｎ−スルホニルアミノチアゾール | |
| CN101014570A (zh) | 吡啶衍生物或其药学上可接受的盐 | |
| MX2008009668A (en) | Amido compounds and their use as pharmaceuticals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090302 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090302 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120508 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20121113 |